Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 28, 2015 7:54 AM ET

Healthcare Providers and Services

Company Overview of Personal Genome Diagnostics, Inc.

Company Overview

Personal Genome Diagnostics, Inc. engages in the patient-specific analyses of cancer genome using digital characterization and monitoring technologies. The company provides METDetect Assay for the detection of MET gene amplifications in the circulation of cancer patients with reports that include identification and schematic representation of tumor-specific MET amplifications, annotation of predicted mutation consequences, data summary statistics, and integrated analysis reporting. Personal Genome Diagnostics, Inc. was founded in 2010 and is based in Baltimore, Maryland.

855 North Wolfe Street

Suite 629

Baltimore, MD 21205

United States

Founded in 2010

Phone:

410-558-1201

Fax:

410-522-5889

Key Executives for Personal Genome Diagnostics, Inc.

Co-Founder and Chief Medical Officer
Co-Founder and Chief Scientific Officer
Chief Financial Officer
Chief Operating Officer
Age: 47
Chief Commercial Officer
Compensation as of Fiscal Year 2014.

Personal Genome Diagnostics, Inc. Key Developments

Personal Genome Diagnostics, Inc. and Human Longevity, Inc. Sign Cancer Genomics Agreement

Personal Genome Diagnostics, Inc. and Human Longevity, Inc. announced that HLI will have access to PGDx's cancer genomics solutions to expand its analysis of cancer genomes, including CancerSelect, PlasmaSelect, CancerXome, METDetect and CancerComplete. HLI has also licensed the PGDx Enterprise Solution platform, which is a turnkey solution that enables laboratories to conduct their own advanced cancer genomic testing using next-generation sequencing. PGDx applies its advanced genomic methods to identify and characterize the unique genomic alterations in tumors using tissue and liquid biopsies from cancer patients. The ES platform utilizes PGDx's proprietary bioinformatics software pipeline that provides sensitivity and specificity, while maximizing accuracy in detecting multiple types of tumor-specific mutations. PGDx's targeted gene panels focus on well-characterized genes that have been selected for their high biologic importance in cancer and their relevance to drug targets and pathways.

Personal Genome Diagnostics Inc. Announces Management Appointments

Personal Genome Diagnostics Inc. announced a number of senior appointments to support the company's rapid growth. Felix Dawson has joined the company's Board of Directors, Jeffrey Boschwitz, PhD, has been named Chief Operating Officer, and Theresa Zhang, PhD, is the company's new Vice President of Research Services. New Director Felix Dawson is a founding member of Wilkes Lane Capital, a privately held advisory and investment firm. Previously, Mr. Dawson spent 10 years at Constellation Energy (now Exelon), helping build their merchant energy business from start-up into a leading U.S and international player. At Constellation, Mr. Dawson held commercial and senior executive positions including serving as co-CEO of the merchant energy business. Before joining Constellation, Mr. Dawson worked at Goldman Sachs and was a business consultant with Arthur Andersen. Dr. Boschwitz was formerly Executive Vice President, Operations and Corporate Development at cancer pathology company PLUS Diagnostics, where he was responsible for reducing production costs while improving quality and customer satisfaction. Earlier, Dr. Boschwitz was Vice President of North American Sales and Marketing at Orchid Cellmark, a provider of human identity testing that was acquired by LabCorp in 2011. Previously, Dr. Boschwitz was Director, Marketing Planning, Analysis, and Research at Quest Diagnostics, where he led strategic planning, new product development and sales targeting for the $5 billion physician business. Earlier in his career, Dr. Boschwitz was a Principal in the healthcare practice of Booz Allen Hamilton. Dr. Zhang joined the company from Merck Research Laboratories, where she held positions of increasing responsibility for predictive biomarker identification and clinical implementation for oncology compounds for over a decade. During her tenure at Merck, Dr. Zhang oversaw the development of specially designed CLIA assays for use in cancer clinical trials and advanced a number of candidate biomarkers for clinical validation. She also managed multiple external collaborations.

Personal Genome Diagnostics Inc. Launches CancerSelect ES Providing Turnkey Solution for Advanced Cancer Genetic Research

Personal Genome Diagnostics Inc. announced the launch of its CancerSelect(TM) Enterprise Solution (ES) that enables laboratories with next-generation sequencing capability to conduct advanced cancer genetic testing for research applications. CancerSelect ES provides a turnkey solution that includes CancerSelect gene panels, proprietary bioinformatics software, staff training, ongoing technical support, report generation, and panel updates. The two PGDx CancerSelect panels detect alterations in 88 and 203 well-characterized genes that are of high biologic importance in cancer. They have been selected for their relevance to cancer-related drug targets and pathways. The CancerSelect gene panels identify genetic alterations in the targeted genes, including point mutations, copy number alterations and genetic rearrangements. Most other cancer gene tests only identify point mutations, yet all three types of genetic alterations can potentially play a role in disease progression and response to current or future therapies. The CancerSelect gene panels achieve analytical sensitivity of more than 99% for mutations and indels at 2% mutant allele frequency. Their specificity is greater than 99.99%, with a target depth of coverage of more than 1,500.

Similar Private Companies By Industry

Company Name Region
Norcare Enterprises, Inc. United States
AMN Allied Services, LLC United States
Ionia Dialysis, LLC United States
Sanford Hospital Jackson United States
Valley Pain Centers, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Personal Genome Diagnostics, Inc., please visit personalgenome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.